Fortis Healthcare May Appeal Delhi HC Ruling in Daiichi Sankyo Case
Source: ET Real Estate
Arth Insight · What this means for your wallet
- Fortis Healthcare is reviewing a Delhi High Court order concerning the Daiichi Sankyo arbitration.
- The court has mandated a forensic audit of past transactions, creating a potential financial liability for Fortis.
- Fortis Healthcare is considering appealing the ruling to the Supreme Court due to potential compensation obligations.
Fortis Healthcare is reviewing a Delhi High Court order for a forensic audit concerning the Daiichi Sankyo arbitration case. The ruling could lead to a significant contingent liability, potentially requiring Fortis to pay compensation, prompting consideration of an appeal to the Supreme Court.
- ▸Fortis Healthcare is reviewing a Delhi High Court order concerning the Daiichi Sankyo arbitration.
- ▸The court has mandated a forensic audit of past transactions, creating a potential financial liability for Fortis.
- ▸Fortis Healthcare is considering appealing the ruling to the Supreme Court due to potential compensation obligations.
- ▸The outcome could significantly impact Fortis Healthcare's financial position.
- ✓Fortis Healthcare is reviewing a Delhi High Court order concerning the Daiichi Sankyo arbitration.
- ✓The court has mandated a forensic audit of past transactions, creating a potential financial liability for Fortis.
- ✓Fortis Healthcare is considering appealing the ruling to the Supreme Court due to potential compensation obligations.
- ✓The outcome could significantly impact Fortis Healthcare's financial position.
Fortis Healthcare is currently evaluating a recent Delhi High Court ruling related to its arbitration case with Japanese firm Daiichi Sankyo. The court has mandated a forensic audit of past transactions, a development that introduces a notable contingent liability for the Indian healthcare provider.
This legal development stems from a long-standing dispute between Fortis and Daiichi Sankyo, which originated from Daiichi's acquisition of a controlling stake in Fortis Healthcare through its erstwhile parent company, Fortis Health Management, in 2008. Daiichi Sankyo later accused the sellers of misrepresenting the financial health of the acquired entity, leading to arbitration proceedings.
The Delhi High Court's decision to order a forensic audit is a critical step in the ongoing legal battle. Such an audit aims to scrutinize the financial dealings and transactions that occurred during the period relevant to the dispute. The outcome of this audit could have significant financial implications for Fortis Healthcare.
Specifically, the court's order raises the possibility that Fortis Healthcare might be required to directly compensate Daiichi Sankyo. This potential financial obligation is the primary reason why Fortis is considering taking the matter to the Supreme Court. An appeal would seek to challenge the High Court's ruling and potentially mitigate or avoid the financial repercussions.
The company's management is reportedly assessing the full impact of the ruling and exploring all available legal avenues. The decision to appeal will depend on the detailed analysis of the court's order and its potential financial consequences. Investors and stakeholders will be closely watching this development as it could affect Fortis Healthcare's financial standing.
This report is for informational purposes only and does not constitute investment advice.
Loan interest rates, processing fees and eligibility are set by the lender and subject to credit approval — verify current terms before applying. Some listings may be sponsored. Not financial advice.
Frequently Asked Questions
What is the dispute between Fortis Healthcare and Daiichi Sankyo about?
The dispute relates to Daiichi Sankyo's acquisition of a stake in Fortis Healthcare, where Daiichi later alleged misrepresentation of the company's financial health by the sellers.
What did the Delhi High Court order?
The Delhi High Court ordered a forensic audit of earlier transactions related to the case.
Why might Fortis Healthcare appeal to the Supreme Court?
Fortis Healthcare is considering an appeal because the High Court's ruling could lead to a direct compensation payment to Daiichi Sankyo.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about real-estate
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
Related Stories
NITI Aayog Eyes Policy Reforms to Boost India's Medical Device Manufacturing
NITI Aayog is actively exploring new policy measures to enhance India's domestic manufacturing capabilities for medical and dental devices. The initiative addresses significant hurdles like complex regulations and cost disadvantages faced by local producers. The goal is to strengthen the 'Make in India' drive within the crucial healthcare sector.
Health Ministry Ordered to Probe Coronary Stent Safety Concerns by Cabinet Secretariat
The Cabinet Secretariat has directed the Union Health Ministry to investigate safety concerns surrounding coronary stents. This action follows concerns raised by Rajya Sabha member Ajeet Madhavrao Gopchade, highlighting issues with models withdrawn in Sri Lanka and calling for a stronger regulatory framework in India.
Biocon to Launch Cancer Drug Pebrilzo in EU/UK by 2027, US by 2028 After Settlement
Biocon has resolved all legal disputes with Genentech regarding its cancer drug Pebrilzo through a global settlement and license agreement. This crucial development paves the way for Biocon to launch Pebrilzo in the European Union and the United Kingdom by early 2027, followed by the United States in the third quarter of 2028.
BreakingHospitals, Clinics May Soon Prominently Display Service Rates
Health Secretary Punya Salila Srivastava has urged state and UT health authorities to mandate prominent display of service rates by hospitals and clinics. This move aims to help patients and their attendants understand treatment costs, make informed financial decisions, and plan their healthcare spending more effectively.